San Diego, California–(Newsfile Corp. – December 16, 2022) – Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid...
San Diego, California–(Newsfile Corp. – December 13, 2022) – Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing proprietary, synthetic cannabinoid derivatives,...
San Diego, California–(Newsfile Corp. – November 22, 2022) – Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid...
San Diego, California–(Newsfile Corp. – November 17, 2022) – Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing proprietary, synthetic cannabinoid derivatives,...
– Recruitment for cohort 1 has begun – Clinical trial material manufactured and shipped to Australia San Diego, California–(Newsfile Corp. – November 16, 2022) – Skye...
San Diego, California–(Newsfile Corp. – November 10, 2022) – Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid...
Additional capital from Arrangement Agreement expected to fund Skye’s Phase 1 and 2 clinical studies of proprietary synthetic cannabinoid-derivative therapeutic targeting glaucoma San Diego, California–(Newsfile Corp....
Lead drug candidate has shown superior and longer-lasting lowering of intraocular pressure, a risk factor associated with glaucoma, in preclinical studies San Diego, California–(Newsfile Corp. –...